ArticleCancer immunology research2019
Mapping the MHC Class I-Spliced Immunopeptidome of Cancer Cells.
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing.Nature communications · 2024Article
- Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example.Seminars in immunology · 2023Review
- Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.Nature biotechnology · 2023Article
- InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides.Scientific data · 2023Article
- iBench: A ground truth approach for advanced validation of mass spectrometry identification method.Proteomics · 2023Article
- Immunolyser: A web-based computational pipeline for analysing and mining immunopeptidomic data.Computational and structural biotechnology journal · 2023Article
- A luminescence-based method to assess antigen presentation and antigen-specific T cell responses forFrontiers in immunology · 2023Article
- Review
- Predicting the Success of Fmoc-Based Peptide Synthesis.ACS omega · 2022Article
- A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources.Cancers · 2022Article
- Article
- Identification of tumor antigens with immunopeptidomics.Nature biotechnology · 2022Review
- Review
- Mechanistic diversity in MHC class I antigen recognition.The Biochemical journal · 2021Review
- Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides.Cell reports · 2021Article
- Noncontiguous T cell epitopes in autoimmune diabetes: From mice to men and back again.The Journal of biological chemistry · 2021Review
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.International journal of molecular sciences · 2021Review
- Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.Nature communications · 2021Article
- Spliced HLA-bound peptides: a Black Swan event in immunology.Clinical and experimental immunology · 2021Review
- In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.eLife · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Anticancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines. The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.